Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has seen a massive down tick in the past few trading sessions, and we believe that this downward trajectory might continue for the stock and may lead it to lower levels. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock performance was 5.41% in last session and finished the day at $9.51. Traded volume was 20,914.00million shares in the last session and the average volume of the stock remained 210.62K shares.
Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) will present at the 13th Annual Needham Healthcare Conference in New York City . The event is scheduled to begin at 3:40 PM ET April 9, 2014. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) rose percent to $7.24 Friday on volume of 32,786.00million shares. The intra-day range of the stock was $6.66 to $7.61. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has a market capitalization of $65.78 million.
Heat Biologics Inc (NASDAQ:HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company presented results of two preclinical ImPACT Therapy based research studies at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held April 5-9, 2014 in San Diego. Heat Biologics Inc (NASDAQ:HTBX)’s stock on Apr 11, 2014 reported a increase of 9.60% to the closing price of $5.71. Its fifty two weeks range is $5.01-$15.29. The total market capitalization recorded $36.84million. The overall volume in the last trading session was 31,065.00million shares. In its share capital, HYBX has 6.45million outstanding shares.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) climbed $0.83 (or +6.38%) to $13.84, following the announcement that the company has been granted a patent in Hong Kong for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” On Friday, shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) advanced 6.38% to close the day at $13.84. Company return on investment (ROI) is % and its monthly performance is recorded as 20.56%. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) quarterly revenue growth is -52.13%.